Exscientia Management

Management Kriterienprüfungen 1/4

Exscientia's CEO ist Dave Hallett , ernannt in Feb 2023, hat eine Amtszeit von 1.33 Jahren. besitzt direkt 0.001% der Aktien des Unternehmens, im Wert von €7.22K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.4 Jahre bzw. 3.5 Jahre.

Wichtige Informationen

Dave Hallett

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	1.3yrs
Eigentum des Geschäftsführers	0.001%
Durchschnittliche Amtszeit des Managements	1.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.5yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Dave Hallett (55 yo)

1.3yrs

Amtszeit

Dr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
David Hallett	Chief Scientific Officer	1.3yrs	keine Daten	0.0012% £ 7.4k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	3.6yrs	UK£1.92m	0.039% £ 241.8k
John Overington	Chief Technology Officer	no data	keine Daten	keine Daten
Eileen Jennings-Brown	Chief Information Officer	2yrs	keine Daten	keine Daten
Sara Sherman	Vice President of Investor Relations	no data	keine Daten	keine Daten
Dan Ireland	Executive VP of Legal & Company Secretary	1.4yrs	keine Daten	keine Daten
Parker Moss	Executive Vice President of Corporate Development	less than a year	keine Daten	keine Daten
Caroline Rowland	Chief People Officer	1.8yrs	keine Daten	keine Daten
Richard Law	Chief Business Officer	no data	keine Daten	keine Daten
Nikolaus Krall	Executive Vice President of Precision Medicine	1.4yrs	keine Daten	keine Daten
Marie-Louise Fjallskog	Interim Chief Medical Officer & Clinical Development Lead	no data	keine Daten	keine Daten

1.4yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: 0RKDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.4 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
David Hallett	Chief Scientific Officer	less than a year	keine Daten	0.0012% £ 7.4k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	3.6yrs	UK£1.92m	0.039% £ 241.8k
Elizabeth Crain	Interim Independent Non-Executive Chairman	3.3yrs	UK£282.03k	0.056% £ 348.0k
Mario Polywka	Independent Non-Executive Director	6.8yrs	UK£201.69k	0.046% £ 285.1k
Robert Ghenchev	Independent Non-Executive Director	4.1yrs	keine Daten	keine Daten
Franziska Michor	Independent Director	1.1yrs	UK£178.86k	0.0052% £ 32.6k

3.5yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrener Vorstand: 0RKDie Vorstandsmitglieder gelten als erfahren (3.5 Jahre durchschnittliche Amtszeit).

Exscientia Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Exscientia plc, Annual General Meeting, May 15, 2024

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Exscientia plc, Annual General Meeting, May 18, 2022

Recent updates

The Schall Law Firm Announces Class Action Lawsuit Against Exscientia plc

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.38 loss in 1Q 2023)

Exscientia plc to Report Q1, 2024 Results on May 21, 2024

Holzer & Holzer, LLC Files Class Action Lawsuit on Behalf of Exscientia P.L.C. Investors

Exscientia plc, Annual General Meeting, May 15, 2024

New minor risk - Shareholder dilution

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Full year 2023 earnings released: UK£1.18 loss per share (vs UK£0.97 loss in FY 2022)

Exscientia plc to Report Fiscal Year 2023 Results on Mar 21, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: UK£0.25 loss per share (vs UK£0.29 loss in 3Q 2022)

Exscientia plc to Report Q3, 2023 Results on Nov 09, 2023

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc to Present New Preclinical Data for AI- Designed LSD1 and MALT1 Inhibitors at ESMO 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 2Q 2022)

Exscientia plc to Report Q2, 2023 Results on Aug 10, 2023

Exscientia plc Initiates Prospective Observational Study in Ovarian Cancer

Exscientia plc Announces First Patient Enrolled in Phase 1/2 ELUCIDATE Trial Assessing GTAEXS617 in Advanced Solid Tumours

First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.17 loss in 1Q 2022)

Exscientia plc Highlights "The Future of AI-Enabled Drug Discovery" at SLAS Europe

Exscientia plc to Report Q1, 2023 Results on May 24, 2023

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Full year 2022 earnings released: UK£0.97 loss per share (vs UK£0.99 loss in FY 2021)

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

Exscientia plc Highlights New Data to Identify Patients That Are More Likely to Respond to Its A2a Receptor Antagonist, Exs-21546

Exscientia plc Receives First clinical trial application Approval to Initiate IGNITE-AI, Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours

Exscientia plc to Report Q3, 2022 Results on Nov 15, 2022

Blood Cancer Discovery Publication Further Validates Exscientia's Ai Precision Medicine Platform for Improving Patient Outcomes

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Second quarter 2022 earnings released: UK£0.23 loss per share (vs UK£0.71 loss in 2Q 2021)

Exscientia plc to Report Q2, 2022 Results on Aug 17, 2022

Exscientia plc Reports Data from EXS-21546 Phase 1A Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers

Exscientia plc to Report Q1, 2022 Results on May 25, 2022

Exscientia plc, Annual General Meeting, May 18, 2022

Exscientia plc Appoints Michael Krams as Chief Quantitative Medicine Officer

No independent directors

Third quarter 2021 earnings released: UK£0.059 loss per share

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter